


## ➤ EGF-R Mutants offered

wild-type	$\Delta 752-759$
G719S	T790M
$\Delta 746-750/T790M$	T790M/L858R
$\Delta 746-750/C797S$	T790M/C797S/L858R
$\Delta 746-750/T790M/C797S$	L858R
$\Delta 747-749/A750P$	L861Q

## ➤ Assay Technology

Rat1 fibroblasts express the cellular domain of EGF-R Mutants fused to a designed transmembrane domain. The designed transmembrane domain causes a constitutive EGF-R mutant autophosphorylation.




## ➤ Advantages


- same cellular background
- HTS feasible
- standardized assay procedure

## ➤ Study Example

**Figure 1:** Gefitinib and Lapatinib were tested for the inhibition of EGF-R phosphorylation on selected EGF-R mutants. Both compounds lack efficient inhibition of EGF-R mutant T790M and T790M/L858R.



## ➤ You ship your compounds – Reaction Biology performs the testing



- $IC_{50}$  values are determined by testing 8 compound concentrations in semi-logarithmic steps (each concentration in duplicates).
- Quality assurance is provided by calculation of  $Z'$  factors for Low/High controls on each assay plate and by including a full  $IC_{50}$  curve for a reference inhibitor to monitor adequate dose/response relation in your assay run.

➤ EGF-R Mutants carrying the C797S mutation in comparison to some other variants

